colorectal-cancer

Documents about colorectal-cancer

• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries#6802OpenAlex
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries#6803OpenAlex
• dMMR prediction from colorectal cancer histopathology: Leveraging non-tumor and low-magnification regions.#9657PubMed
• Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer#353298ClinicalTrials.gov
• Empowering Latino Communities Through the Colorectal Health Research Champions Model: Enhancing Colorectal Cancer Awareness and Screening Advocacy.#440972NCBI PubMed Central
• Endoscopic Quality Improvement Program#804928ClinicalTrials.gov
• Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer#805043ClinicalTrials.gov
• Application of the behavior change wheel in supporting self-management among colorectal cancer survivors: A scoping review#4537Europe PMC
• Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives#120190Europe PMC
• Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer#143572ClinicalTrials.gov
• The role of the receptor Protein-Tyrosin Kinase 7(PTK7) in colon homeostasis, colitis and carcinogenesis#156065HAL (France)
• Development and External Evaluation of a Five-Gene Macrophage Polarization-Related Prognostic Model for Colorectal Cancer#436132Figshare
• A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment#812152ClinicalTrials.gov
• FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC#830111ClinicalTrials.gov
• Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer#123453ClinicalTrials.gov
• Integrated Single-Cell and Spatial Profiling of MMP Gene Expression in Colorectal Cancer#214777bioRxiv / medRxiv
• Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers#283230ClinicalTrials.gov
• MLL4/KMT2D mutations increase immune activity and predict therapyefficacy in colorectal cancer#627782bioRxiv / medRxiv
• Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study#810461ClinicalTrials.gov
• Long Term Effect of Oxaliplatin Treatment in Cancer Survivors#829141ClinicalTrials.gov
• Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor#779914ClinicalTrials.gov
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors#811070ClinicalTrials.gov
• Stromal Regulation of Colorectal Cancer Plasticity#390591Zenodo (CERN)
• NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer#471453ClinicalTrials.gov
• Special Combination of BBI608 and Pembrolizumab#828889ClinicalTrials.gov
• Unraveling the nexus in the neuro-neoplastic progression of colorectal cancer: Potential role of β2-adrenergic receptor (β2-AR)#208583Europe PMC
• Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer#217018ClinicalTrials.gov
• Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer#804346ClinicalTrials.gov
• The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study#828298ClinicalTrials.gov
• Development of a Clinical and Biological Database in Rectum Cancer#805924ClinicalTrials.gov
• Hunting for microsatellite instability in long-read data with Owl#637006PLOS
• A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies#127579ClinicalTrials.gov
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer#394757ClinicalTrials.gov
• Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC#136317ClinicalTrials.gov
• Should Multi-Cancer Early Detection Testing Replace Guideline-Recommended Colorectal Cancer Screening? A Comparative Modeling Analysis#448079bioRxiv / medRxiv
• BESPOKE Study of ctDNA Guided Immunotherapy#808104ClinicalTrials.gov
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer#290989ClinicalTrials.gov
• Differences and similarities in breast and colorectal screening participation: a spatial and temporal analysis to reveal intervention areas, France#326021HAL (France)
• Image 2_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.tiff#353666Figshare
• Table 2_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353667Figshare
• Table 12_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353668Figshare
• Table 13_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353669Figshare
• Table 4_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353670Figshare
• Table 3_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353671Figshare
• Table 1_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353672Figshare
• Table 6_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353673Figshare
• Table 5_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353674Figshare
• Table 7_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353675Figshare
• Table 8_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.xlsx#353676Figshare
• Image 3_Cross-sectional gut microbiota and serum metabolite differences across clinically defined groups in colorectal cancer.tif#353677Figshare